Imagine a high-tech replacement pipe for blood that doesn't just sit there, but talks to the doctor. It uses special coatings to stop blood clots and infections, acting like a smart shield. Built-in sensors act like a security system, alerting medics if something goes wrong while a patient is treating themselves at home.
Current dialysis grafts fail up to 70% of the time due to infection and clotting. This forces patients to stay in hospitals, as home dialysis is too risky without real-time monitoring.
A biomimetic arteriovenous graft with zwitterion coatings and drug delivery. It includes integrated pressure and optical sensors connected to an AI-powered telemonitoring dashboard.
If you are a graft manufacturer dealing with the fact that 70% of current grafts fail in the first year—this project developed a biomimetic graft that prevents thrombosis and infection. This allows for a product with significantly higher long-term success rates.
If you are a digital health provider dealing with the lack of real-time data for home dialysis—this project developed AI machine learning models and a dashboard. This enables remote consultations and monitoring for patients far from clinics.
If you are a clinic operator dealing with overcrowded facilities—this project developed a smart graft system that makes home dialysis safe. This allows you to transition patients from hospital-based HD to home settings.
Based on available project data, specific pricing or cost per unit is not mentioned; however, it is positioned as a simpler and cheaper alternative to kidney transplantation in low-income settings.
Based on available project data, partner Biomodics has already established a reactor to manufacture the grafts for testing, indicating a move toward scalable production.
Based on available project data, there is no specific mention of patents or licensing terms, though the project involves 13 partners including 3 industry entities.
The system integrates via a dashboard accessible on multiple platforms, allowing healthcare professionals to perform online telemonitoring and remote consultations.
The project runs from 2022-09-01 to 2027-02-28, including a 2-stage randomized clinical trial with 60 patients.
The consortium is well-balanced for commercialization, featuring 13 partners across 7 countries. With an industry ratio of 23% (3 companies, including 3 SMEs), there is a clear bridge between the 4 universities and 3 research centers and the market. The inclusion of specialized partners like Biomodics for manufacturing and Verigraft for tissue integration suggests a complete value chain from production to clinical validation.
Contact the research department at SYDDANSK UNIVERSITET
Contact us to explore licensing opportunities for the smart graft sensors.
